Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer

Summary

This is a prospective, open-label, single arm translational study of cabazitaxel in bone Castration Resistant metastatic Pancreatic Cancer (mCRPC) patients. Patient will be treated with intravenous (iv) cabazitaxel 25mg/m2 every (q) 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).

Timeline

Start

2015-10-29

Primary completion

2019-12

Completion

2019-12-27

Drugs

Indications